



Dr. Janet L. Gunzner-Toste is currently a Senior Director of Program Management leading drug development teams at Nektar Therapeutics. Janet previously worked at Genentech starting in 2003, first serving as a Medicinal Chemist and then as Chemistry Team Leader on drug discovery teams before moving to drug development as a Senior Project Manager in the Portfolio Management and Operations Department. Before joining Genentech, she was a Senior Research Chemist in the Medicinal Chemistry Department at Merck. She has been responsible for several pipeline projects spanning oncology, immunology, and neurodegenerative therapeutic areas at various stages of clinical development. Janet has co-authored more than 30 publications for professional journals and is listed as an inventor on more than 30 patents. She was a co-inventor of Erivedge® (vismodegib), a medicine used to treat advanced or metastatic basal cell carcinoma which was approved by the FDA in 2012. Janet earned a B.A. in chemistry from Reed College in 1993 and a PhD in chemistry from the Scripps Research Institute in 1999, and was a National Institutes of Health postdoctoral fellow in chemistry at Stanford University. Janet has been the recipient of the Roche Excellence in Chemistry Prize and the ACS Heroes of Chemistry Award for the discovery of Erivedge®. In her free time, she is finishing her MBA at the Haas School of Business at UC Berkeley, and she enjoys spending time with her two children and her husband, Dean Toste, who is a professor of chemistry at the University of California at Berkeley.